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Neisseria meningitidis is one of the leading causes of bacterial meningitis globally and can also cause sepsis,
pneumonia, and other manifestations. In countries with high endemic rates, the disease burden places an immense
strain on the public health system. The worldwide epidemiology of invasive meningococcal disease (IMD) varies
markedly by region and over time. This review summarizes the burden of IMD in different countries and identifies the
highest-incidence countries where routine preventive programs against Neisseria meningitidis would be most beneficial
in providing protection. Available epidemiological data from the past 20 years in World Health Organization and
European Centre for Disease Prevention and Control collections and published articles are included in this review, as
well as direct communications with leading experts in the field. Countries were grouped into high-, moderate-, and
low-incidence countries. The majority of countries in the high-incidence group are found in the African meningitis belt;
many moderate-incidence countries are found in the European and African regions, and Australia, while low-incidence
countries include many from Europe and the Americas. Priority countries for vaccine intervention are high- and
moderate-incidence countries where vaccine-preventable serogroups predominate. Epidemiological data on burden of
IMD are needed in countries where this is not known, particularly in South- East Asia and Eastern Mediterranean
regions, so evidence-based decisions about the use of meningococcal vaccines can be made.
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Meningitis beltIntroduction
Neisseria meningitidis is one of the leading causes of bac-
terial meningitis globally and can also cause sepsis, pneu-
monia, and other localized infections. There are 12
serogroups, but the majority of invasive meningococcal in-
fections are caused by organisms from the A, B, C, X, Y,
or W-135 serogroups. The annual number of invasive dis-
ease cases worldwide is estimated to be at least 1.2 million,
with 135,000 deaths related to invasive meningococcal dis-
ease (IMD) [1,2]. In countries with high endemicity, the
disease burden places an immense strain on the public
health system. The risk of long-term disabling sequelae,
including cognitive deficit, bilateral hearing loss, motor
deficit, seizures, visual impairment, hydrocephalus, and* Correspondence: asad.ali@aku.edu
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reproduction in any medium, provided the orloss of limbs due to tissue necrosis, are highest in low-
income countries, where the burden of bacterial meningi-
tis is greatest [3].
To combat IMD, many industrialized countries have in-
cluded different formulations of meningococcal vaccine in
their routine immunization programs. A vaccine against
serogroup A has recently been introduced in the African
meningitis belt, an area extending from Senegal in the
west to Ethiopia in the east [4,5]. However, meningococcal
vaccines remain underutilized globally, particularly in
resource-limited countries outside the African meningitis
belt. To provide cost effective recommendations about the
use of meningococcal vaccines, the country-specific bur-
den of IMD must be established [6]. A comprehensive re-
view of IMD incidence, including all countries with at
least a basic surveillance infrastructure reporting IMD
cases, was conducted. The review provides the most re-
cently published attack rates, predominant serogroups, and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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data according to priority groups for vaccine intervention.
Methods
Search strategy and selection criteria
Our sources for the epidemiological data included the
National Library of Medicine (PubMed), the World
Health Organization (WHO) website of the Weekly
Epidemiological Record, and the European Centre for
Disease Prevention and Control. We searched PubMed
with the following key terms: (“Neisseria meningitidis”)
OR (“meningococcal”) OR (“meningococcemia”) OR
(“meningococcus”). The search was limited to studies
of humans, studies published in English, and dates of pub-
lication from January 1, 1990, to December 31, 2010. The
initial search yielded 5,336 results from which studies
were excluded based on exclusion criteria below. In
addition, data were obtained and included from WHO
publications in the Weekly Epidemiological Record (WER)
for the latest figures from 14 African meningitis belt coun-
tries. The European Union Invasive Bacterial Infections
Surveillance Network (EU-IBIS), which is maintained by
the European Centre for Disease Prevention and Control,
was accessed for updated figures for European countries
and these data were also included. We searched reference
lists in all identified articles for additional articles, and
reviewed abstracts and titles and selected studies if it
seemed they included aspects of meningococcal epidemi-
ology. From the above literature search we excluded gen-
eric worldwide estimates (except to identify original data
references), or studies that were limited to immunology,
drug resistance, or other non-epidemiological factors.
Organization of data
The WHO definition of a meningococcal disease epi-
demic (>100 cases/100,000 population/year) applies spe-
cifically to the meningitis belt. Other countries rarely
experience epidemics with these high attack rates. We
classified countries according to the level of endemic
meningococcal disease as “high,” “moderate,” and “low”
endemicity (Figure 1). This classification is based on
country-specific epidemiological data with pre-defined
cutoffs of high, moderate, and low endemicity categoriesV
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Figure 1 A categorization of countries according to IMD attack rates.and was used by the WHO’s Strategic Advisory Group
of Experts on Immunizations (SAGE) in its recently
updated recommendations on the use of meningococcal
vaccines [7].
Results
Epidemiology of meningococcal disease at country level
Data on incidence of meningococcal disease are presented
below in Tables 1, 2 and 3. Countries are grouped into pri-
ority regions according to the definitions above, using na-
tional and published data from the last 20 years. Countries
not listed in the table have insufficient available IMD epi-
demiological data to permit accurate classification.
Significant gaps in data limit description of IMD epi-
demiology in some parts of the world. In many countries
with IMD surveillance, extensive targeted vaccine devel-
opment and increasing coverage has decreased the bur-
den of disease. In some endemic countries without
vaccination, high IMD attack rates continue. The spe-
cific regional epidemiology is summarized in Figure 2
and described in terms of WHO regions below.
African region
The African Meningitis Belt, originally characterized by
Lapeysonnie in 1963 [5] and modified in 1987, has the
highest annual incidence of meningococcal disease in the
world with superimposed frequent epidemics that consti-
tute a major public health burden. Outbreaks in the sub-
Saharan region coincide with the dry season, which has
led to a hypothesis for the potential role of low humidity
and seasonal dust-wind blowing from the Sahara (the
Harmattan) in damaging the mucosa and producing irri-
tant coughing that aids transmission [34,43].
Twenty-five countries in the African region with an
extremely high incidence of meningococcal disease con-
stitute the meningitis belt. To rapidly detect the frequent
epidemics, a strong surveillance system exists that moni-
tors the number of cases on an ongoing basis for rapid
response. This region has recently benefitted from a
major alliance of international health bodies that have
developed and are deploying an affordable and effective
vaccine against serogroup A meningococcus, which causes
the majority of disease in this area, at population level [44].Countries with high endemic rates 
and/or >= 1 epidemic over the past 
20 years
Countries with moderate endemic 
rates
Countries with low endemic rate
Table 1 Countries with high endemic rates (>10 cases/100,000 population) and/or > =1 epidemic over the last 20 years
Country Year Incidence/100,000
population
Predominant
serogroup
Source Comments
African Region
Angola 1994–2000 19–230 * [8]
Benin 1980–1999 6–57 [9,10]
Burkina Faso 2004–2009 26–187 [11,12]
Burundi
1980–1999
158 [9]
Cameroon 1–224 [13]
Centrafique
2004–2009
3 3–19.4 [12]
Chad 9.6–15.9 [12]
Cote de Ivoire
1980–1999
0-6 [14]
Despite its relatively low attack
rate, Cote de Ivoire is included
in this table due to its location in
the meningitis belt
Ethiopia 0–104 A [9,10]
Gambia 4–165 [9,15]
Ghana 0–108 [9,15]
Guinea 0–17 [12]
Guinea Bissau 0–133 [9]
Kenya 1990 267 [16]
Mali 2004–2009 2.6–12.9 [12]
Mauritania
1980–1999
0–14 [9]
Namibia 4–165 [9]
Niger
2004–2009
7.8–90.7 [17]
Nigeria 0.7–52.6 [12]
RD Congo 7.3–23.7 [12]
Rwanda
1980–1999
0–28 [9]
Senegal 0–53 Incidence >50 in 1983
Tanzania 1980–1999 0–19
Togo 2004–2009 6–13.2 [12]
Uganda 1980–1999 0–18 [14]
Eastern Mediterranean Region
Sudan 2008 * A [12]
Despite lack of data Sudan is
included in this table due
to its location in the meningitis
belt
Saudi Arabia 2000 A, W-135 [18]
225 cases in month after 2000
Hajj season. Data from Saudi
Arabia mostly includes cases
from the Hajj season.
European Region
No country in this region is in the high rate category
Region of the Americas
Uruguay 2001
30 (pre-vaccine)
B [19]
Vaccine comprising serogroup C
capsular polysaccharide and
the outer membrane vesicles
of serogroup B meningococcus
was used
1.6 (post-vaccine)
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Table 1 Countries with high endemic rates (>10 cases/100,000 population) and/or > =1 epidemic over the last 20 years
(Continued)
South-East Asia Region
No country in this region is in the high rate category
Western Pacific Region
New Zealand 1991–2000
17.4 (pre-vaccine)
B [20]
An OMV vaccine for Serogroup
B was introduced in 20042.6 (post-vaccine)
Mongolia 1994–1995 80-90 A [21]
* Data not available.
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gitis, has been responsible for outbreaks between 2006 and
2010 in Kenya, Niger, Togo, Uganda, and Burkina Faso, the
latter with at least 1,300 cases of serogroup X meningitis
among the 6,732 reported annual cases [45].
South Africa is included in the moderate-endemicity
group, while other countries in this region do not have
adequate data to enable derivation of a population-based
estimate of their true incidence rates.
Eastern Mediterranean region
Sudan and Saudi Arabia have high endemic rates of
serogroup A disease, and have also experienced outbreaks in
recent years during the hajj season with serogroup W-135.
Other countries in this region do not have adequate data to
permit a population-based estimate of true incidence,
although outbreaks have been reported among returning
travelers from Hajj.
European region
With the exception of a few countries in the eastern part of
the European Region, good surveillance data are available
from most European countries. Serogroup B and C are re-
sponsible for the majority of disease, and implementation
of a meningococcal immunization program with adequate
vaccine coverage has contributed to decreasing endemic
rates so that no country now falls in the high-endemicity
group. Fifteen countries from this region are classified as
moderate endemicity and 18 as low. Recent epidemiological
surveillance indicates an increase of serogroup Y IMD in
some parts of Europe, which is now the third most com-
mon serogroup after B and C [23].
Region of the Americas
Uruguay remains the only country from this region to have
experienced high rates of IMD within the past 20 years. In
2001, it suffered a peak incidence rate of meningococcal dis-
ease due to serogroup B and this prompted the introduction
of the Cuban outer membrane vesicle (OMV) B vaccine with
good coverage and a sharp decline in incidence in subse-
quent years. Brazil and Cuba have experienced moderate in-
cidence rates, but have also seen significant benefit from the
introduction of meningococcal vaccines in their populations[29]. Argentina, Canada, Chile, Columbia, Mexico, the
United States, and Venezuela have experienced low levels of
IMD in the timeframe defined by this review. Serogroup Y
emerged in Colombia and Venezuala, where it became the
common disease-causing serogroup in 2006 [19]. The US
has a universal meningococcal vaccine (conjugated quadriva-
lent vaccine given to adolescents) and Canada also recom-
mends a booster dose in this age group following primary
immunization at 12 months of age. Other countries in this
region do not have adequate data to allow population-based
estimates of their true incidence.
South-East Asia Region
Korea and Thailand are the only countries from this region
with published population-based estimates, which demon-
strate low endemic rates. India has experienced repeated
serogroup A epidemics, the most recent in 2005, but data
are mostly available only from large city centers [46]. Spor-
adic and incomplete data from India, Bangladesh, Indonesia,
Nepal, and Pakistan preclude their classification, and no data
are available from Sri Lanka [36].
Western Pacific
New Zealand and Mongolia have recorded high IMD
endemicity. New Zealand experienced an outbreak of
serogroup B disease until an aggressive campaign with
the OMV vaccine was initiated in 2004 that has con-
tributed in part to lowering the incidence. Mongolia
experienced serogroup A epidemics in the early 1990s.
Australia currently experiences predominantly serogroup
B disease with moderate attack rates after the introduction
of a serogroup C vaccine saw a marked decline in rates of
disease due to the C serogroup. China, Japan, Korea,
Philippines, Singapore, Taiwan, and Thailand all experi-
ence low levels of IMD. Other countries in this region do
not have adequate population-based data to allow estima-
tion of their true incidence rates.
Age-specific attack rates
In many countries with epidemiological data, particularly
in Europe and North America, the age distribution of
meningococcal disease demonstrates two peaks [6,47-49].
The highest incidence is in infants less than one year of
Table 2 Countries with moderate endemic rates (2–10 cases/100,000 population per year)
Country Year Incidence/
100,000 population
Predominant
serogroup
Source Comments
African Region
South Africa 2000–2005 0.8–4 B in Western Cape [22]
Eastern Mediterranean Region
No country in this region is in the moderate rate category
European Region
Belgium 1999–2010
2.9 (pre-vaccine)
B, C [23,24]
A conjugate vaccine for group
C was introduced in 20020.89 (post-vaccine)
Denmark 1999–2010 1.19–3.5 B [23,24]
Greece 0.49–2.0 C [23,24]
A conjugate vaccine for group
C introduced in 2001 in pediatric
population[25]
Ireland 14.3 (pre-vaccine) B, C [23,24] A conjugate vaccine for group
C was
2.19 (post-vaccine) introduced in 2001
Iceland 7.6 (pre-vaccine) B, C [23,24] A conjugate vaccine for group
C was
0.6 (post-vaccine) introduced in 2002
Lithuania 2004–2010 1.4–2.6 * [23,24]
Luxemburg 1999–2010 0.2–5.68 * [23,24]
Malta 1994–2007 0.8–8.9 B, C [26] 2 peaks in 2000 and 2006
Netherland 1999–2010
3.6 (pre-vaccine)
B, C [23,24]
A conjugate vaccine for group
C was introduced in 20020.86 (post-vaccine)
Norway 1992–2010 0.8–4.6 B [23,27]
Portugal 2000–2010 0.74–3.0 B, C [23,28]
Spain 1999–2010
3.52 (pre-vaccine)
B, C [23,24]
A conjugate vaccine for group
C introduced in 20010.88 (post vaccine)
Switzerland 1999–2004 1.16–2.36 C [24] A conjugate vaccine for group
C introduced in 2005
Turkey 1997–2005 0.3–2.2 * [28]
United Kingdom 1999–2010
5.4 (pre-vaccine)
B, C [23,24]
A conjugate vaccine for group
C introduced in 19991.63 (post vaccine)
Region of the Americas
Brazil 1998–2006 1–4.5 B, now C [19]
A combined vaccine against
serogroup B (OMV) and
C (polysaccharide) was introduced
in 1990
Cuba 1998–2003
3.4-8.5 (pre-vaccine)
B [29]
A combined vaccine against
serogroup B (OMV) and C
(polysaccharide) was introduced
in 1987
<1 (post-vaccine)
South-East Asia Region
No country in this region is in the moderate rate category
Western Pacific Region
Australia 1995–2006
3.5–7.9 (pre-vaccine)
B [30]
A conjugate vaccine for Serogroup
C was introduced in 20031.4 (post-vaccine)
* Data not available.
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Table 3 Countries with low endemic rates (<2 case/100,000 population per year)
Country Year Incidence/100,000 population Predominant serogroup Source Comments
African Region
No country in this region is in the low rate category
European Region
Austria 1999–2010 1.02–1.2 B, C [23,24]
Bulgaria 2000–2010 0.11–1.1 * [23,28]
Croatia 1997–2005 0.7–1.3 * [28]
Cyprus 1997–2010 0.13–1.7 * [23,28]
Czech Republic 1999–2010 0.57–1.0 B, C [23,24]
Estonia 2001–2010 0.15–1.6 * [23,28]
Finland
1999–2010
0.64–1.1 B
[23,24]
France 0.7–1.13 B, C
Germany 0.47–0.73 B, C
Hungary 2004–2010 0.3–0.4 *
Italy 1999–2010 0.25–0.55 B, C
Latvia 2004–2008 0.25–1.03 *
Poland 1999–2010 0.17–0.84 B
Serbia 2000 0.9 * [28]
Slovakia 2004–2010 0.59–0.9 *
[23,24] [23,24]Slovenia 1999–2010 0.3–1.2 *
Sweden 2004–2010 0.5–0.7 B, C
Eastern Mediterranean Region
No country in this region is in the low rate category
Region of the Americas
Argentina 2009 0.6 B [31]
Canada 1985–2006
1.4 (pre-vaccine)
C [32,33] Vaccination in 2001–2 in all provinces
0.4 (post-vaccine)
Chile
1998–2006
0.8 B
[19]Columbia 0.3 Y
Mexico 0.1 C
USA 2000–2009
0.8 (pre-vaccine)
Equal B, C,Y [34] Routine vaccination program started in 2005
0.3 (post-vaccine)
Venezuela 0.3 Y [19]
South-East Asia Region
Korea 2002–2008 <0.1 [35]
Thailand 2007–2008 <0.1 [36] Higher in <5 year olds
Western Pacific Region
China 2000 onward <0.2 A, C [37,38]
Japan 1999–2004 <0.02 * [39]
Philippines 2004–2008 <0.1 A [1]
Singapore 2005–2009 0.1–0.2 [36,40] 25/100,000 in Hajj pilgrims in 2000 [41]
Taiwan 2000–2001 0.1–0.2 A [42]
Eastern Mediterranean Region
No country in this region is in the low rate category
*Data not available.
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B, C
Figure 2 Distribution of common and predominant meningococcal serogroups by region. Predominant strains are highlighted in
bold text.
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http://www.pophealthmetrics.com/content/11/1/17age, and a secondary rise in incidence occurs in adoles-
cents and young adults. In one study in the meningitis
belt, the age-incidence did not plateau until the late 20s.
Fifteen years of data from Niger show that children under
the age of five were more affected during epidemics when
compared to non-epidemic years [50]. However, some
studies have suggested a shift toward older age groups
during epidemics [51].
The widespread and rapid use of effective antibiotics
has contributed to bringing down the case fatality rate of
IMD to between 10 and 20 percent, but it is generally
higher in developing countries where access to higher
levels of care may be delayed [52]. Despite advances in
resuscitative techniques, surgical intervention, and crit-
ical care, there is a persistent mortality in the early hours
of septicemia due to the rapid progression of disease.
Conclusion
IMD is a serious illness that can be rapidly progressive
with resulting significant morbidity and mortality, even
with treatment. Vaccines are available for the majority of
serogroups that cause disease and have proven effective
in reducing the disease incidence in countries that have
applied them at the population level. Maximizing the
global impact of these vaccines requires having them
made available in regions that have the highest disease
incidence.
This review used available data to define the burden of
meningococcal disease in different countries. Countries
were classified based on the disease endemicity, andavailable data on the most prevalent serogroups were
reviewed to permit evidence-based decisions on menin-
gococcal vaccine use. These data helped inform SAGE’s
new recommendations on the use of meningococcal vac-
cines. Limitations of the review include exclusion of
studies that were not published in English and the ab-
sence of an indicator of the quality of surveillance used
to derive incidence rates. It is crucial that timely surveillance
utilizing new molecular epidemiology tools is implemented
to obtain epidemiological data on burden of meningococcal
disease in countries where these are not known. With
the licensing of a new affordable conjugated vaccine
against serogroup A (licensed in Africa) and, more re-
cently, a multicomponent serogroup B vaccine in Europe
(January 2013), functioning surveillance will be necessary
to monitor the impact of these vaccines through direct
immunity and herd protection and allow for optimization
of vaccination schedules.
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